Antidepressant-like effect of a Kampo (Japanese herbal) medicine, kososan, against the interferon-α-induced Depressive-like model mice

Journal of Traditional Medicines

Volumn 25, Issue 3, 2008, Pages 74-80

  Nagai, Takayuki ^a   Narikawa, Teruyo ^a,b   Ito, Naoki ^a   Takeda, Tadahiro ^b   Hanawa, Toshihiko ^a   Yamada, Haruki ^a  

^a KITASATO UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

depression; HPA axis; interferon ; Kampo medicine; kososan

Indexed keywords

EID: 70350036950     PISSN: 18801447     EISSN: 18813747     Source Type: Journal    
DOI: 10.11339/jtm.25.74     Document Type: Article

References (49)

1. Gisslinger, H., Svoboda, T., Clodi, M., Gilly, B., Ludwig, H., Havelec, L. and Luger, A.: Interferon-α stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology 57, 489-495, 1993.
2. Sen, G. C. and Lengyel, P.: The interferon system. A bird's eye view of its biochemistry. J. Biol. Chem. 267, 5017-5020, 1992.
3. Pestka, S.: The human interferon α species and receptors. Biopolymers 55, 254-287, 2000.
4. Calvet, M. C. and Gresser, I.: Interferon enhances the excitability of cultured neurones. Nature 278, 558-560, 1979.
5. Krueger, J. M., Dinarello, C. A., Shoham, S., Davenne, D., Walter, J. and Kubillus, S.: Interferon alpha-2 enhances slow-wave sleep in rabbits. Int. J. Immunopharmacol. 9, 23-30, 1987.
6. Koyanagi, S. and Ohdo, S.: Alteration of intrinsic biological rhythms during interferon treatment and its possible mechanism. Mol. Pharmacol. 62, 1393-1399, 2002.
7. Schrott, L. M. and Crnic, L. S.: Increased anxiety behaviors in autoimmune mice. Behav. Neurosci. 110, 492-502, 1996.
8. Renault, P. F., Hoofnagle, J. H., Park, Y., Mullen, K. D., Peters, M., Jones, D. B., Rustgi, V. and Jones, E. A.: Psychiatric complications of long-term interferon alfa therapy. Arch. Intern. Med. 147, 1577-1580, 1987.
9. Pestka, S.: The interferons. 50 years after their discovery, there is much more to learn. J. Biol. Chem. 282, 20047-20051, 2007.
10. Raison, C. L., Demetrashvili, M., Capuron, L. and Miller, A. H.: Neuropsychiatric adverse effects of interferon-α. Recognition and management. CNS Drugs 19, 105-123, 2005.
11. Gohier, B., Goeb, J. L., Rannou-Dubas, K., Fouchard, I., Cales, P. and Garre, J. B.: Hepatitis C, alpha interferon, anxiety and depression disorders. A prospective study of 71 patients. World J. Biol. Psychiatry 4, 115-118, 2003.
12. Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A., Ling, M. H. and Albrecht, J.: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339, 1493-1499, 1998.
13. McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M. H., Cort, S. and Albrecht, J. K.: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339, 1485-1492, 1998.
14. Miyaoka, H., Otsubo, T., Kamijima, K., Ishii, M., Onuki, M. and Mitamura, K.: Depression from interferon therapy in patients with hepatitis C. Am. J. Psychiatry 156, 1120, 1999.
15. Pariante, C. M., Orru, M. G., Baita, A., Farci, M. G. and Carpiniello, B.: Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders. Lancet 354, 131-132, 1999.
16. Bonaccorso, S., Puzella, A., Marino, V., Pasquini, M., Biondi, M., Artini, M., Almerighi, C., Levrero, M., Egyed, B., Bosmans, E., Meltzer, H. Y. and Maes, M.: Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 105, 45-55, 2001.
17. Horsmans, Y.: Interferon-induced depression in chronic hepatitis C. J. Antimicrob. Chemother. 58, 711-713, 2006.
18. Makino, M., Kitano, Y., Hirohashi, M. and Takasuna, K.: Enhancement of immobility in mouse forced swimming test by treatment with human interferon. Eur. J. Pharmacol. 356, 1-7, 1998.
19. Makino, M., Kitano, Y., Komiyama, C. and Takasuna, K.: Human interferon-α increases immobility in the forced swimming test in rats. Psychopharmacology (Berl.) 148, 106-110, 2000.
20. Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B. and Miller, A. H.: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 344, 961-966, 2001.
21. Hauser, P., Khosla, J., Aurora, H., Laurin, J., Kling, M. A., Hill, J., Gulati, M., Thornton, A. J., Schultz, R. L., Valentine, A. D., Meyers, C. A. and Howell, C. D.: A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol. Psychiatry 7, 942-947, 2002.
22. Kraus, M. R., Schafer, A., Faller, H., Csef, H. and Scheurlen, M.: Paroxetine for the treatment of interferon-α-induced depression in chronic hepatitis C. Aliment. Pharmacol. Ther. 16, 1091-1099, 2002.
23. Hanawa, T.: Kososan and Hangekobokuto. Journal of Kampo Medicine 42, 418-426, 1995.
24. Ito, N., Nagai, T., Yabe, T., Nunome, S., Hanawa, T. and Yamada, H.: Antidepressant-like activity of a Kampo (Japanese herbal) medicine, Koso-san (Xiang-Su-San), and its mode of action via the hypothalamic-pituitary-adrenal axis. Phytomedicine 13, 658-667, 2006.
25. Porsolt, R. D., Bertin, A. and Jalfre, M.: Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 229, 327-336, 1977.
26. Makino, M., Kitano, Y., Komiyama, C., Hirohashi, M., Kohno, M., Moriyama, M. and Takasuna, K.: Human interferon-α induces immobility in the mouse forced swimming test. Involvement of the opioid system. Brain Res. 852, 482-484, 2000.
27. Mochizuki, D., Tsujita, R., Yamada, S., Kawasaki, K., Otsuka, Y., Hashimoto, S., Hattori, T., Kitamura, Y. and Miki, N.: Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology (Berl.) 162, 323-332, 2002.
28. Kato R., Murakami C., Inoue M., Kamata K. and Nakamura M.: The influences of dopamine receptor antagonists on caffeine induced behavioral stimulant effect in rats. J. Kyorin Med. Soc. 32, 133-139, 2001.
29. Zoon, K. C., Miller, D., Bekisz, J., zur Nedden, D., Enterline, J. C., Nguyen, N. Y. and Hu, R. Q.: Purification and characterization of multiple components of human lymphoblastoid interferon-α. J. Biol. Chem. 267, 15210-15216, 1992.
30. De La Garza, R., 2nd, Asnis, G. M., Pedrosa, E., Stearns, C., Migdal, A. L., Reinus, J. F., Paladugu, R. and Vemulapalli, S.: Recombinant human interferon-α does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 781-792, 2005.
31. Blalock, J. E. and Smith, E. M.: Human leukocyte interferon (HuIFN-α). Potent endorphin-like opioid activity. Biochem. Biophys. Res. Commun. 101, 472-478, 1981.
32. Dunn, A. L. and Crnic, L. S.: Repeated injections of interferon-α A/D in Balb/c mice. Behavioral effects. Brain Behav. Immun. 7, 104-111, 1993.
33. Gold, P. W., Goodwin, F. K. and Chrousos, G. P.: Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (1). N. Engl. J. Med. 319, 348-353, 1988.
34. Nemeroff, C. B.: The corticotropin-releasing factor (CRF) hypothesis of depression. New findings and new directions. Mol. Psychiatry 1, 336-342, 1996.
35. Barden, N., Reul, J. M. and Holsboer, F.: Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci. 18, 6-11, 1995.
36. Heuser, I.: Anna-Monika-Prize paper. The hypothalamic-pituitary-adrenal system in depression. Pharmacopsychiatry 31, 10-13, 1998.
37. Holsboer, F. and Barden, N.: Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr. Rev. 17, 187-205, 1996.
38. Corssmit, E. P., Heijligenberg, R., Endert, E., Ackermans, M. T., Sauerwein, H. P. and Romijn, J. A.: Endocrine and metabolic effects of interferon-α in humans. J. Clin. Endocrinol. Metab. 81, 3265-3269, 1996.
39. Menzies, R., Phelps, C., Wiranowska, M., Oliver, J., Chen, L., Horvath, E. and Hall, N.: The effect of interferon-alpha on the pituitary-adrenal axis. J. Interferon Cytokine Res. 16, 619-629, 1996.
40. Wichers, M. and Maes, M.: The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int. J. Neuropsychopharmacol. 5, 375-388, 2002.
41. Besedovsky, H. O. and del Rey, A.: Immune-neuro-endocrine interactions. Facts and hypotheses. Endocr. Rev. 17, 64-102, 1996.
42. Pariante, C. M. and Miller, A. H.: Glucocorticoid receptors in major depression. Relevance to pathophysiology and treatment. Biol. Psychiatry 49, 391-404, 2001.
43. Billiau, A., Heremans, H., Ververken, D., van Damme, J., Carton, H. and de Somer, P.: Tissue distribution of human interferons after exogenous administration in rabbits, monkeys, and mice. Arch. Virol. 68, 19-25, 1981.
44. Collins, J. M., Riccardi, R., Trown, P., O'Neill, D. and Poplack, D. G.: Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys. Comparison of intravenous, intramuscular, and intraventricular delivery. Cancer Drug Deliv. 2, 247-253, 1985.
45. Banks, W. A., Kastin, A. J. and Broadwell, R. D.: Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 2, 241-248, 1995.
46. Kitagami, T., Yamada, K., Miura, H., Hashimoto, R., Nabeshima, T. and Ohta, T.: Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats. Role of nitric oxide as a signal crossing the blood-brain barrier. Brain Res. 978, 104-114, 2003.
47. Wang, J., Campbell, I. L. and Zhang, H.: Systemic interferon-α regulates interferon-stimulated genes in the central nervous system. Mol. Psychiatry 13, 293-301, 2008.
48. Kaneko, N., Kudo, K., Mabuchi, T., Takemoto, K., Fujimaki, K., Wati, H., Iguchi, H., Tezuka, H. and Kanba, S.: Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology 31, 2619-2626, 2006.
49. Schafer, M., Schmidt, F., Amann, B., Schlosser, S., Loeschke, K. and Grunze, H.: Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis. Neuropsychobiology 42 Suppl. 1, 43-45, 2000.